Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merrimack Pharmaceuticals and CTCA Partner in Multifaceted Collaboration

Published: Tuesday, July 03, 2012
Last Updated: Tuesday, July 03, 2012
Bookmark and Share
Partnership to advance translational research and individualized treatment.

Merrimack Pharmaceuticals, Inc. and the Cancer Treatment Centers of America® (CTCA) have announced that they have formed a unique and wide ranging partnership to advance their long-term vision of individualized treatment - where diagnosis and therapy is guided by an in-depth understanding of the underlying mechanism of a patient’s disease.

The collaboration encompasses research on diagnostics based on a network signaling approach to analyzing patients’ tumors as well as clinical trial research.

For the diagnostic research, CTCA will contribute archived tumor biopsies from their extensive tumor databank as well as prospectively collected tumor samples.

These samples will be analyzed using Merrimack’s Network Biology approach to identifying the network signaling that drives cancer growth with the goal of understanding each patient’s cancer at the molecular level.

Many of CTCA’s patients are battling advanced cancer and have received many prior lines of therapy.

This makes CTCA’s tumor archive particularly unique as they offer an opportunity for Merrimack to explore how the molecular characteristics of a tumor change as a result of therapy.

This joint effort eventually could lead to the identification of novel companion diagnostics to guide treatment decisions.

“Every day, experts at CTCA provide personalized care to advanced and late-stage cancer patients. This partnership with Merrimack supports our goal to give every patient an individually focused treatment plan, using innovative technologies and tools to help fight their cancer and improve their quality of life,” said Maurie Markman, M.D., Senior Vice President of Clinical Affairs & National Director of Medical Oncology at CTCA.

Markman continued, “We believe that the innovations that come from this partnership could help provide the right treatment for every patient’s unique biology.”

“Access to CTCA’s tumor samples greatly enhances the speed and scope of the research we are doing to understand the complexity of cancer cells and to characterize what their growth is dependent upon,” says Robert Mulroy, CEO of Merrimack Pharmaceuticals.

Mulroy continued, “CTCA is a great example of a forward-looking institution trying to change the face of cancer care. This collaboration represents the future of individualized treatment where a hospital and a biopharmaceutical company work together on research, which we hope will ultimately result in much better treatment for cancer patients.”

The collaboration also encompasses clinical research. Merrimack will collaborate with CTCA investigators to take advantage of the rich clinical expertise at CTCA through participation in and collaboration on clinical studies of Merrimack therapeutics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Studies Explore Science of Cardiovascular Diseases
Two studies highlight how basic science research insights are key to future treatment breakthroughs.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Stem Cells Growing 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
MRI Guidance Aids Stem Cell Delivery
Scientists have delivered stem cells to the brain with unprecedented precision, infusing the cells under real-time MRI guidance.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Stem Cell Transplant Without Radiation or Chemotherapy
Researchers have successfully performed stem cell transplants without using radiation or chemotherapy.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
Inherited Heart Condition Breakthrough
Using stem cells, scientists have created a specific heart condition model, yeilding insights into unexpected disease mechanisms.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!